Transforming growth factor-beta receptor type 2 mRNA (TGFBR2 mRNA)

Transforming growth factor-beta receptor type 2 (TGFBR2) mRNA is the messenger RNA transcript that encodes the TGFBR2 protein, a critical transmembrane serine/threonine kinase receptor. This receptor is essential for the TGF-beta signaling pathway, which regulates diverse cellular processes including proliferation, differentiation, and apoptosis (UniProt P37173). In many advanced cancers, the TGF-beta pathway is hijacked to promote epithelial-mesenchymal transition (EMT), metastasis, and immune evasion, making the reduction of receptor expression a viable therapeutic strategy (PMID: 25635394). Targeting the mRNA directly via antisense oligonucleotides (ASOs) or small interfering RNAs (siRNAs) allows for the potent knockdown of the receptor protein, potentially overcoming the limitations of small molecule kinase inhibitors (PMID: 30333116). However, because TGF-beta signaling also acts as a tumor suppressor in early-stage tissues, therapeutic intervention must be carefully timed and targeted. Beyond oncology, TGFBR2 mRNA is a target of interest in fibrotic diseases where overactive TGF-beta signaling drives excessive extracellular matrix deposition.

Other names

TGF-beta receptor type II mRNATGFBR2 transcriptTbetaR-II mRNATGFB-R2 mRNA

RNA interference (RNAi) or antisense-mediated degradation of mRNA to prevent the translation of the TGF-beta receptor type 2 protein, thereby inhibiting TGF-beta signaling.